Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
6.54 -0.79 (-10.78%) 04/01/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 6.92 +0.38 (+5.81%) 17:41 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.50
Day High
7.41
Open 7.29
Previous Close 7.33 7.33
Volume 1,885,100 1,885,100
Avg Vol 1,761,525 1,761,525
Stochastic %K 12.29% 12.29%
Weighted Alpha -20.51 -20.51
5-Day Change -0.99 (-13.15%) -0.99 (-13.15%)
52-Week Range 4.06 - 11.77 4.06 - 11.77
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,165,631
  • Shares Outstanding, K 159,022
  • Annual Sales, $ 63,720 K
  • Annual Income, $ -193,510 K
  • EBIT $ -172 M
  • EBITDA $ -168 M
  • 60-Month Beta 1.34
  • Price/Sales 18.92
  • Price/Cash Flow N/A
  • Price/Book 3.78

Options Overview Details

View History
  • Implied Volatility 93.40% ( +23.43%)
  • Historical Volatility 90.49%
  • IV Percentile 68%
  • IV Rank 27.11%
  • IV High 252.21% on 06/12/24
  • IV Low 34.35% on 06/11/24
  • Put/Call Vol Ratio 0.44
  • Today's Volume 442
  • Volume Avg (30-Day) 783
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 24,690
  • Open Int (30-Day) 26,223

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 6
  • High Estimate -0.25
  • Low Estimate -0.30
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.78 +13.05%
on 03/04/25
Period Open: 7.14
8.92 -26.68%
on 03/12/25
-0.60 (-8.40%)
since 02/28/25
3-Month
5.78 +13.05%
on 03/04/25
Period Open: 8.54
9.22 -29.07%
on 01/07/25
-2.00 (-23.42%)
since 12/31/24
52-Week
4.06 +61.08%
on 04/26/24
Period Open: 8.69
11.77 -44.46%
on 10/28/24
-2.15 (-24.74%)
since 04/01/24

Most Recent Stories

More News
Ocular Therapeutixâ„¢ to Participate in Two Investor Conferences in April

OCUL : 6.54 (-10.78%)
Why Ocular Therapeutix Was Bumping Higher This Week

The market was seeing Ocular Therapeutix (NASDAQ: OCUL) very positively this week, and that sunny view pushed the company's stock higher.

OCUL : 6.54 (-10.78%)
Ocular Therapeutixâ„¢ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

OCUL : 6.54 (-10.78%)
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback

The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.

VXF : 173.18 (+0.53%)
VTI : 275.77 (+0.34%)
IWM : 199.51 (+0.01%)
OCUL : 6.54 (-10.78%)
Ocular Therapeutix: Q4 Earnings Snapshot

Ocular Therapeutix: Q4 Earnings Snapshot

OCUL : 6.54 (-10.78%)
Ocular Therapeutixâ„¢ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

OCUL : 6.54 (-10.78%)
Ocular Therapeutixâ„¢ to Present at Two Investor Conferences in March

OCUL : 6.54 (-10.78%)
Ocular Therapeutixâ„¢ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

OCUL : 6.54 (-10.78%)
Ocular Therapeutixâ„¢ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

OCUL : 6.54 (-10.78%)
Ocular Therapeutixâ„¢ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

OCUL : 6.54 (-10.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 8.04
2nd Resistance Point 7.72
1st Resistance Point 7.13
Last Price 6.54
1st Support Level 6.22
2nd Support Level 5.91
3rd Support Level 5.32

See More

52-Week High 11.77
Fibonacci 61.8% 8.83
Fibonacci 50% 7.92
Fibonacci 38.2% 7.01
Last Price 6.54
52-Week Low 4.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies